The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: Results of a multicentre open-label study

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 34-40

  Santos Gómez, Montserrat ^a   Calvo Río, Vanesa ^a   Blanco, Ricardo ^a   Beltrán, Emma ^b   Mesquida, Marina ^c   Adán, Alfredo ^c   Cordero Coma, Miguel ^d   García Aparicio, Ángel M ^e   Pascual, Elia Valls ^f   Martínez Costa, Lucía ^f   Hernández, María Victoria ^c   Garfella, Marisa Hernandez ^b   González Vela, María C ^a   Pina, Trinitario ^a   Palmou Fontana, Natalia ^a   Loricera, Javier ^a   Hernández, José L ^a   González Gay, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

^e Hospital de Toledo   (Spain)

^f Hospital Peset Valencia   (Spain)

Author keywords

Beh et's disease; Biologic therapy; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; TOCILIZUMAB; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BEHCET DISEASE; BIOLOGICAL ACTIVITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INFLAMMATION; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUSSENBLAT SCALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITRITIS; BEHCET SYNDROME; CLINICAL TRIAL; DRUG RESISTANCE; DRUG SUBSTITUTION; IMMUNOLOGY; MIDDLE AGED; REMISSION; SPAIN; TIME FACTOR; TREATMENT OUTCOME; UVEITIS;

ADALIMUMAB; ADULT; AGED; BEHCET SYNDROME; BIOLOGICAL PRODUCTS; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; MIDDLE AGED; REMISSION INDUCTION; SPAIN; TIME FACTORS; TREATMENT OUTCOME; UVEITIS;

EID: 85012830018     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. KITAICHI N, MIYAZAKI A, IWATA D, OHNO S, STANFORD MR, CHAMS H: Ocular features of Behçet's disease: An international collaborative study. Br J Ophthalmol 2007; 91: 1579-82.
2. SAKANE T, TAKENO M, SUZUKI N, INABA G: Behçet's disease. New Engl J Med 1999; 341: 1284-91.
3. TUGAL-TUTKUN I, ONAL S, ALTANYAYCIOGLU R, HUSEYIN ALTUNBAS H, URGANCIOGLU M: Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138: 373-80.
4. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
5. öZDAL PC, ORTAç S, TASKINTUNA I, FIRAT E: Long-term therapy with low dose cyclosporine A in ocular Behçet's disease. Doc Ophthalmol 2002; 105: 301-12.
6. YAZICI H, PAZARLI H, BARNES CG et al.: A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990; 322: 281-5.
7. ZIERHUT M, SAAL J, PLEYER U, KöTTER I, DüRK H, FIERLBECK G: Behçet's disease: epidemiology and eye manifestations in German and Mediterranian patients. Ger J Ophthalmol 1995; 4: 246-51.
8. PIVETTI PEZZI P, GASPARRI V, DE LISO P, CATARINELLI G: Prognosis in Behçet's disease. Ann Ophthalmol 1985; 17: 20-5.
9. OKADA AA, GOTO H, OHNO S, MOCHIZUKI M: Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet's disease. Arch Ophthalmol 2012; 130: 592-8.
10. SUGITA S, YAMADA Y, MOCHIZUKI M: Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease. Br J Ophthalmol 2011; 95: 549-52.
11. KEINO H, OKADA AA, WATANABE T, TAKI W: Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet's disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245-50.
12. TUGAL-TUTKUN I, MUDUN A, URGANCIOGLU M et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 2478-84.
13. NICCOLI L, NANNINI C, BENUCCI M et al.: Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46: 1161-64.
14. DíAZ-LLOPIS M, SALOM D, GARCIA-de-VICUñA C et al.: Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119: 1575-81.
15. BAWAZEER A, RAFFA LH, NIZAMUDDIN SH: Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010; 18: 226-32.
16. TAKASE K, OHNO S, IDEGUCHI H, UCHIO E, TAKENO M, ISHIGATSUBO Y: Successful switching to adalimumab in an infliximaballergic patient with severe Behçet's diseaserelated uveitis. Rheumatol Int 2011; 31: 243-5.
17. PERRA D, ALBA MA, CALLEJAS JL et al.: Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) 2012; 51: 1825-31.
18. LEVY-CLARKE G, JABS DA, READ RW, ROSENBAUM JT, VITALE A, VAN GELDER RN: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785-96.
19. CALVO-RíO V, BLANCO R, BELTRáN E et al.: Anti-TNF-a therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014; 53: 2223-31.
20. PASADHIKA S, ROSENBAUM JT: Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 2014; 8: 67-81.
21. PAROLI MP, ABBOUDA A, ABBICA I, SAPÌA A, PAROLI M: Biological agents in the treatment of uveitis. Adv Biosci Biotechnol 2013; 4: 64-72.
22. MESQUIDA M, VICTORIA HERNáNDEZ M, LLORENç V et al.: Behçet Disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 2013; 2: 160-2.
23. CORDERO-COMA M, CALVO-RíO V, ADáN A et al.: Golimumab as rescue therapy for refractory immune-mediated uveitis: a three center experience. Mediators Inflamm 2014; 2014: 717598.
24. DAVATCHI F, SHAMS H, REZAIPOOR M et al.: Rituximab in intractable ocular lesions of Behçet's disease, randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13: 246-52.
25. SADREDDINI S, NOSHAD H, MOLAEEFARD M, NOSHAD R: Treatment of retinal vasculitis in Behçet's disease with rituximab. Mod Rheumatol 2008; 18: 306-8
26. HIRANO T, OHGURO N, HOHKI S et al.: A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22: 298-302.
27. International Study group for Behçet's Dis ease: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
28. DESCHENES J, MURRAY PI, RAO NA, NUSSENBLATT RB: International Uveitis Study Group (IUSG) clinical classification of uveitis. Ocul Immunol Inflamm 2008; 16: 1-2.
29. CORDERO COMA M, DíAZ LLOPIS M: Estrategia inmunosupresora en situaciones especiales, Pauta ante brotes y reactivaciones durante el tratamiento anti-TNF. En GEMUSEDU. Uveitis, Protocolos diagnósticos y nuevas estrategias terapéuticas, Valencia: Díaz Llopis M, 2011, p177-180.
30. JABS DA, NUSSENBLATT RB, ROSENBAUM JT: The standardization of uveitis nomenclature (SUN) working group; Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. J Ophthalmol 2005; 140: 509-16.
31. NUSSENBLATT RB, PALESTINE AG, CHAN CC, ROBERGE F: Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467-71.
32. Al RASHIDI S, Al FAWAZ A, KANGAVE D, ABU El-ASRAR AM: Long-term clinical outcomes in patients with refractory uveitis associated with Behçet's disease treated with infliximab. Ocul Immunol Inflamm 2013; 21: 468-74.
33. CAPELLA MJ, FOSTER CS: Long-term efficacy and safety of infliximab in the treatment of Behçet's disease. Ocul Immunol Inflamm 2012; 20: 198-202.
34. ZLATANOVIC G, JOVANOVIC S, VESELINOVIC D, ZIVKOVIC M: Efficacy of TNFalpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behçet's disease and HLA B51 positive vasculitis. Vojnosanit Pregl 2012; 69: 168-74.
35. MISEROCCHI E, MODORATI G, PONTIKAKI I, MERONI P, GERLONI V: Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 2013; 31: 320-1.
36. CORDERO-COMA M, SALOM D, DIAZLLOPIS M, LOPEZ-PRATS MJ, CALLEJA S: Golimumab for uveitis. Ophthalmology 2011; 118: 1892.
37. CALVO-RíO V, de la HERA D, BLANCO R et al.: Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 2014; 32: 864-8.
38. HEILIGENHAUS A, MISEROCCHI E, HEINZ C, GERLONI V, KOTANIEMI K: Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal anti body (rituximab). Rheumatology (Oxford) 2011; 50: 1390-4.
39. OLIVIERI I, LECCESE P, D'ANGELO S et al.: Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011; 29 (Suppl. 67): S54-7.
40. BENITAH NR, SOBRIN L, PAPALIODIS GN: The use of biologic agents in the treatment of ocular manifestations of Behçet's disease. Semin Ophthalmol 2011; 26: 295-303.
41. CASO F, COSTA L, RIGANTE D et al.: Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm 2014; 2014: 107421.
42. PAPO M, BIELEFELD P, VALLET H et al.: Tocilizumab in severe and refractory noninfectious uveitis. Clin Exp Rheumatol 2014; 32 (Suppl. 84): S75-9.
43. CALVO-RíO V, de la HERA D, BELTRáNCATALáN E et al.: Tocilizumab in uveítis refractory to other biologic drugs: a study of 3 cases and literature review. Clin Exp Rheumatol 2014; 32 (Suppl. 84): S54-7.
44. ADAN A, MESQUIDA M, LLORENC V et al.: Tocilizumab treatment for refractory uveitisrelated cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2627-32.
45. CASO F, IACCARINO L, BETTIO S et al.: Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunologic Research 2013; 56: 390-7.
46. LLORENç V, MESQUIDA M, SAINZ de la MAZA M et al.: Certolizumab Pegol, a New Anti-TNF-a in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm 2014; 17: 1-6.
47. MAIZ ALONSO O, BLANCO ESTEBAN AC, EGüES DUBUC CA, MARTINEZ ZABALEGUI D: Effectiveness of certolizumab pegol in chronic anterior uveitis associated to Crohn's disease and ankylosing spondylitis. Reumatol Clin 2015; 11: 189-90.
48. FURUTA S, CHOW YW, CHAUDHRY AN, JAYNE D: Switching of anti TNF alfa agents in Behçet's disease. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S62-S68.
49. SMOLEN JS, KAY J, DOYLE MK et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, doubleblind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
50. HYRICH KL, LUNT M, DIXON WG, WATSON KD, SYMMONS DPM; on behalf of the BSR Biologics Register: Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008; 47: 1000-5.
51. GALOR A, PEREZ VL, HAMMEL JP, LOWDER CY: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006; 11: 2317-23.
52. WENDLING D, PACCOU J, BERTHELOT JM et al.: New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011; 4: 503-10.
53. ZIERHUT M, ABU EL-ASRAR AM, BODAGHI B, TUGAL-TUTKUN I: Therapy of ocular Behçet's disease. Ocul Immunol Inflamm 2014; 22: 64-76.
54. ALEXOUDI I, KAPSIMALI V, VAIOPOULOS A, KANAKIS M, VAIOPOULOS G: Evaluation of current therapeutic strategies in Behçet's disease. Clin Rheumatol 2011; 30: 157-63.
55. GUILLAUME-CZITROM S, BERGER C, PAJOT C, BODAGHI B, WECHSLER B, KONE-PAUT I: Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology (Oxford) 2007; 46: 1570-3.
56. HAZIROLAN D, STüBIGER N, PLEYER U: Light on the horizon: biologicals in Behçet's uveitis. Acta Ophthalmol 2013; 91: 297-306.